SOX2 and glioblastoma: Our results indicate that prevention of SRR2 activity leads to a reduction of oncogenic properties promoted by SOX2, suggesting that SRR2 may represent a novel therapeutic target in the treatment of GBM, to tackle GSCs, and hence relapse of these lethal tumors.